aibioCorcept Therapeutics
Top story · Sep 23, 2026 · SEC filing 8-K
Corcept Therapeutics Incorporated reports a leadership change
On September 22, 2026, Sean Maduck, the President of Corcept Endocrinology, notified the Board of Directors of Corcept Therapeutics Incorporated (the “Company”) of his decision to resign effective as of October 1, 2026.
- Ticker
- CORT
- Listing
- NASDAQ, United States
- Next date
- Fourth quarter of 2026
- Chief executive
- Joseph K. Belanoff, M.D.
Desk view · Opinion · Updated Oct 22, 2026
Corcept's cancer launch is working. December decides the rest
Corcept returned to profit in the second quarter and has added a fast-growing cancer drug to an aging Cushing's franchise. The December FDA decision on relacorilant in Cushing's syndrome will show whether it can replace Korlym before generics erode it. Legal cases and launch spending are the costs to watch.
Read the full desk viewaibio.space Investor Rank · Opinion
8/10 Positive view
Back in profit with a fast-growing cancer launch, while Korlym generics and a December Cushing's decision after a prior rejection decide how well the base is defended.
- Technology
- 2/2
- Odds
- 1/2
- Balance sheet
- 2/2
- Risk
- 1/2
- Momentum
- 2/2
Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. How the rank works.
- Technology
- Proven in two diseases. Korlym treats Cushing's syndrome, and Lifyorli cut the risk of death 35% in a phase 3 ovarian cancer trial.
- Odds
- Mixed near term. EU approval of Lifyorli looks likely after a positive CHMP opinion, but the Cushing's decision follows a prior rejection.
- Balance sheet
- Back in profit. Corcept earned $43.0 million in Q2 after a $31.8 million loss in Q1, and held $544.6 million in cash and investments.
- Main risk
- Korlym generics. Teva's generic is on the market, and more could follow under settlements with Sun and Hikma.
- Watch next
- December FDA decision. The relacorilant Cushing's decision is due by Dec. 17, 2026.
Top news on Corcept
Questions investors ask
What is aibio.space's Investor Rank for Corcept Therapeutics?
8 out of 10, our positive view. Back in profit with a fast-growing cancer launch, while Korlym generics and a December Cushing's decision after a prior rejection decide how well the base is defended. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. Source
What is Lifyorli?
Lifyorli is relacorilant, Corcept's selective glucocorticoid receptor antagonist, approved by the FDA in March 2026 with nab-paclitaxel for platinum-resistant ovarian cancer. It brought in $47.6 million in its first quarter on the market. Source
When is the FDA decision on relacorilant for Cushing's syndrome?
The FDA set a PDUFA target date of December 17, 2026, after Corcept resubmitted the application on June 17, 2026. The first application received a complete response letter on December 30, 2025. Source
What is Corcept's 2026 revenue guidance?
In July 2026 Corcept raised its 2026 revenue guidance to $1.1 billion to $1.2 billion. Second-quarter revenue was $256.1 million, up 32% from a year earlier. Source
Who is Corcept's CEO?
Joseph K. Belanoff, M.D., is Corcept's chief executive officer. In September 2026 the company named Justin Gunn president of its endocrinology division, succeeding the retiring Sean Maduck. Source
Does Korlym face generic competition?
Yes. Teva launched a generic version of Korlym in January 2024, and an appeals court affirmed the ruling in Teva's favor in February 2026. Corcept also sells its own authorized generic. Source
What is Corcept Therapeutics's market cap?
We do not publish live share prices. In its annual report, Corcept Therapeutics Incorporated put the market value of shares held by non-affiliates (public float) at $6.11 billion as of Jun 30, 2025. Source
Is Corcept Therapeutics a smaller reporting company?
SEC records list Corcept Therapeutics Incorporated's filer category as: Large accelerated filer. Source
Where is Corcept Therapeutics headquartered?
SEC records list its business address as 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065. Source
When does Corcept Therapeutics's fiscal year end?
Corcept Therapeutics Incorporated's fiscal year ends on December 31, per SEC records. Source
What did Corcept Therapeutics last file with the SEC?
Its most recent filing in our record is an 8-K filed 2026-09-23. All of its filings are on SEC EDGAR. Source
What industry is Corcept Therapeutics in?
Its SEC industry code (SIC 2834) is Pharmaceutical Preparations. Source
Legal and investor matters
- Litigation
Federal Circuit denies Corcept rehearing in Teva Korlym patent case
The Federal Circuit affirmed on 2026-02-19 a district court ruling that Teva's generic Korlym does not infringe Corcept's '214 or '800 patents. Corcept petitioned for rehearing en banc on 2026-04-22, and the court denied the petition on 2026-07-10. Teva launched its generic in January 2024. Corcept says it will continue to enforce its intellectual property rights relating to Korlym.
- Regulatory
DOJ declines to intervene in qui tam action against Corcept
Corcept disclosed that on 2026-05-19 it learned the Department of Justice had filed a notice declining to intervene in a qui tam action, U.S. ex rel. Stephen Elliott v. Corcept, No. 17-CV-1303, in the District of New Jersey. A former employee initiated the case in February 2017, and the DOJ issued a records subpoena in November 2021. The 10-Q filed for the quarter ended 2026-06-30 says the action alleged, among other things, that Corcept violated the federal False Claims Act and similar state laws in connection with sales of Korlym. The relator served an amended complaint on 2026-06-02. Corcept says it intends to defend against all of the relator's claims.
- Litigation
Court lets Teva antitrust suit against Corcept proceed; trial set for March 2027
On 2026-05-05 the Northern District of California partly granted and partly denied motions to dismiss in Teva's antitrust suit against Corcept and Optime Care, allowing the case to proceed. Teva alleges violations of federal and state antitrust and unfair business practices laws. Trial is scheduled for March 2027. A related suit by Aetna, Health Care Service Corporation, Humana and Molina in Alameda County Superior Court has no trial date.
- Derivative suit
Shareholder derivative suit filed against Corcept directors and officers
On 2026-04-10 a purported shareholder derivative complaint was filed by Mark LeRiger in the Northern District of California, LeRiger v. Belanoff et al., naming several executive officers, all current directors and one former director as defendants, with Corcept as nominal defendant. Based on the same statements at issue in the securities class action, the complaint asserts claims for Exchange Act violations, breach of fiduciary duty, unjust enrichment, waste of corporate assets and disgorgement of insider trading profits. According to the 10-Q, the action has been stayed pending resolution of the anticipated motion to dismiss in the securities action.
- Class action
Securities class action filed against Corcept over relacorilant NDA statements
On 2026-02-20 the Allegheny County Employees' Retirement System filed a purported securities class action in the Northern District of California against Corcept and certain executive officers. The complaint alleges false and misleading statements and omissions about the relacorilant NDA for hypercortisolism, and asserts a class period from 2024-10-31 to 2025-12-30. Three groups of stockholders have moved for appointment as lead plaintiff. Corcept says it will vigorously defend the case.
- Regulatory
FDA issues complete response letter for relacorilant in hypercortisolism hypertension
Corcept announced on 2025-12-31 that the FDA issued a complete response letter on its NDA for relacorilant as a treatment for hypertension secondary to hypercortisolism. A purported securities class action filed on 2026-02-20 concerns alleged statements about the relacorilant NDA for hypercortisolism. Corcept announced on 2026-06-17 that it had resubmitted its NDA to the FDA for relacorilant as a treatment for patients with Cushing's syndrome.
- Other
Corcept terminates Optime Care distribution agreement effective 2026-01-08
On 2025-10-10 Corcept gave Optime Care notice terminating its Distribution Services Agreement for Korlym and the authorized generic, effective 2026-01-08. Optime had been the exclusive specialty pharmacy distributor. On 2025-06-17 Corcept had told Optime it would cease to be the exclusive provider effective 2025-09-15. Optime is a co-defendant with Corcept in the Teva antitrust suit.
Pipeline
| Program | Indication | Stage |
|---|---|---|
| Lifyorli (relacorilant) + nab-paclitaxel | Platinum-resistant ovarian cancer | FDA approved March 2026; CHMP positive opinion Sept. 2026, EC decision expected Q4 2026 Source |
| Relacorilant | Cushing's syndrome (hypercortisolism) | NDA resubmitted June 17, 2026; PDUFA date Dec. 17, 2026 Source |
| Relacorilant + nab-paclitaxel + bevacizumab (BELLA) | Platinum-resistant and platinum-sensitive ovarian cancer | Phase 2; Part A results by end of 2026 Source |
| Miricorilant (MONARCH) | MASH | Phase 2b, enrollment complete; results by end of 2026 Source |
| Nenocorilant + nivolumab (SYNERGY) | Solid tumors | Phase 1b; results by end of 2027 Source |
Stock chart
SEC filings and registration
- SEC name
- Corcept Therapeutics Inc
- CIK
- 1088856
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- CORT (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Large accelerated filer
- Business address
- 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, CA, 94065
- Phone
- 650.688.8803
- Shares outstanding
- 108,098,397 as of 2026-07-22 (10-Q filed 2026-07-29)
Recent filings
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction